Rapid Determination of Homocysteine by Microchip CE-PAD

Microchip CE-PAD 快速测定同型半胱氨酸

• 批准号: 7052619
• 负责人: Dale M Willard
• 金额: $ 10.14万
• 依托单位: ADVANCED MICROLABS, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2008-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7052619
• 关键词: bioassay; bioengineering /biomedical engineering; biomarker; biomedical equipment development; cardiovascular disorder diagnosis; clinical biomedical equipment; cost effectiveness; diagnosis design /evaluation; early diagnosis; electrochemistry; electrophoresis; homocysteine; human tissue; method development; microfluidics; microprocessor /microchip; plasma; portable biomedical equipment; rapid diagnosis; thiols

DESCRIPTION (provided by applicant): Cardiovascular disease is the number 1 killer in the United States and much of the Western world. Treatment of the disease costs billions of dollars each year and the costs continue to rise exponentially. Many strides have been made toward improving behavioral patterns that put people at risk, however there is still a need to develop methods to detect disease onset at the earliest possible stage. Early detection requires the measurement of a clinically relevant disease biomarker. One such marker that can be measured is homocysteine. Homocyteine is an amino acid involved in the biosynthesis of methionine and has been clinically linked to cardiovascular disease in a number of studies. Existing methods for measurement of homocysteine require expensive instrumentation, are time consuming, and can only be performed in a clinical laboratory. Advanced Microlabs, LLC is developing microfluidic technology for rapid detection of disease biomarkers that will be inexpensive ($1000 instrument, $5/assay) and require very small samples (1-5 microliters). In the current project, we propose to develop an assay for homocysteine starting from whole blood samples. Our technology platform couples electrochemical detection to microchip electrophoresis to provide the desired low-cost, high portability characteristics. During this project, we wiill develop an assay for both total homocysteine and protein-bound homocysteine using this technology. In addition, we will also develop a second microfluidic device that will allow us to isolate cells from whole blood, a requirement for making accurate measurements. The result of this project will be new techology for the measurement of homocysteine as well as continuous generation of cell free media for analysis.

描述（由申请人提供）：心血管疾病是美国和西方世界的大部分杀手。该疾病的治疗每年要花费数十亿美元，费用继续呈指数增长。在改善使人们处于危险之中的行为模式方面取得了许多进步，但是仍然需要开发最早在可能的阶段检测疾病发作的方法。早期检测需要测量临床相关的疾病生物标志物。可以测量的标记是同型半胱氨酸。同叶氨酸是参与蛋氨酸的生物合成的氨基酸，在许多研究中一直与心血管疾病有关。测量同型半胱氨酸的现有方法需要昂贵的仪器，耗时，并且只能在临床实验室中进行。 Advanced Microlabs，LLC正在开发微流体技术，用于快速检测疾病生物标志物，这些疾病生物标志物将是便宜的（$ 1000的仪器，5美元/分析），并且需要很小的样品（1-5个微透明剂）。在当前的项目中，我们建议从全血样品开始开发同型半胱氨酸的测定法。我们的技术平台伴侣电化学检测到微芯片电泳，以提供所需的低成本，高便携性特征。在此项目中，我们使用该技术开发了总型型和蛋白质结合的同型半胱氨酸的测定法。此外，我们还将开发第二个微流体设备，使我们能够将细胞与全血分离，这是进行准确测量的这一要求。该项目的结果将是测量同型半胱氨酸以及连续生成无细胞介质进行分析的新技术。